New systemic treatment paradigms in resectable non-small cell lung cancer and variations in patient access across Europe.
Loading...
Embargo End Date
ICR Authors
Authors
Houda, I
Dickhoff, C
Uyl-de Groot, CA
Reguart, N
Provencio, M
Levy, A
Dziadziuszko, R
Pompili, C
Di Maio, M
Thomas, M
Brunelli, A
Popat, S
Senan, S
Bahce, I
Dickhoff, C
Uyl-de Groot, CA
Reguart, N
Provencio, M
Levy, A
Dziadziuszko, R
Pompili, C
Di Maio, M
Thomas, M
Brunelli, A
Popat, S
Senan, S
Bahce, I
Document Type
Journal Article
Date
2024-03-01
Date Accepted
2024-01-08
Abstract
The treatment landscape of resectable early-stage non-small cell lung cancer (NSCLC) is set to change significantly due to encouraging results from randomized trials evaluating neoadjuvant and adjuvant immunotherapy, as well as adjuvant targeted therapy. As of January 2024, marketing authorization has been granted for four new indications in Europe, and regulatory approvals for other study regimens are expected. Because cost-effectiveness and reimbursement criteria for novel treatments often differ between European countries, access to emerging developments may lead to inequalities due to variations in recommended and available lung cancer care throughout Europe. This Series paper (i) highlights the clinical studies reshaping the treatment landscape in resectable early-stage NSCLC, (ii) compares and contrasts approaches taken by the European Medicines Agency (EMA) for drug approval to that taken by the United States Food and Drug Administration (FDA), and (iii) evaluates the differences in access to emerging treatments from an availability perspective across European countries.
Citation
The Lancet Regional Health - Europe, 2024, 38 pp. 100840 -
Source Title
The Lancet Regional Health - Europe
Publisher
ELSEVIER
ISSN
2666-7762
eISSN
2666-7762
2666-7762
2666-7762